0 items USD 0.00Search
- Did you mean
- chronic lymphoma leukemia
Your search for "Chronic lymphocytic leukemia" gave back 4676 results.
Uramustine (CAS 66-75-1), also known as uracil mustard, is a chemotherapy drug which belongs to the class of alkylating agents. The global market for...
°ä²¹³Ù²¹±ô´Ç²µ:Ìý
MRRPB5
November 2024
Price: USD 3,950.00
Uramustine (CAS 66-75-1), also known as uracil mustard, is a chemotherapy drug which belongs to the class of alkylating agents. The global Uramustine...
°ä²¹³Ù²¹±ô´Ç²µ:Ìý
MRRPB5
April 2023
Price: USD 2,900.00
The global Tioguanine market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from...
°ä²¹³Ù²¹±ô´Ç²µ:Ìý
LPI
April 2025
Price: USD 3,660.00
The global market for Tioguanine was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing...
°ä²¹³Ù²¹±ô´Ç²µ:Ìý
MRRPB5
February 2025
Price: USD 2,900.00
Tioguanine, also known as thioguanine or 6-thioguanine (6-TG) is a medication used to treat acute myeloid leukemia (AML), acute lymphocytic leukemia...
°ä²¹³Ù²¹±ô´Ç²µ:Ìý
MRRPB5
June 2024
Price: USD 2,900.00
Tioguanine, also known as thioguanine or 6-thioguanine (6-TG) is a medication used to treat acute myeloid leukemia (AML), acute lymphocytic leukemia...
°ä²¹³Ù²¹±ô´Ç²µ:Ìý
MRRPB5
January 2023
Price: USD 2,900.00
The global market for Venetoclax API was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031,...
°ä²¹³Ù²¹±ô´Ç²µ:Ìý
MRRPB5
February 2025
Price: USD 2,900.00
Venetoclax(CAS：1257044-40-8) is an oral selective BCL-2 inhibitor and antineoplastic agent used in the therapy of refractory chronic lymphocytic...
°ä²¹³Ù²¹±ô´Ç²µ:Ìý
MRRPB5
June 2024
Price: USD 2,900.00
The global Idelalisib (CAL-101) market size was valued at US$ million in 2023. With growing demand in downstream market, the Idelalisib (CAL-101) is...
°ä²¹³Ù²¹±ô´Ç²µ:Ìý
LPI
June 2024
Price: USD 3,660.00
Venetoclax(CAS：1257044-40-8) is an oral selective BCL-2 inhibitor and antineoplastic agent used in the therapy of refractory chronic lymphocytic...
°ä²¹³Ù²¹±ô´Ç²µ:Ìý
MRRPB5
May 2023
Price: USD 2,900.00
According to our latest study, the global Idelalisib (CAL-101) market size was valued at USD million in 2023 and is forecast to a readjusted size of...
°ä²¹³Ù²¹±ô´Ç²µ:Ìý
GIR
November 2024
Price: USD 3,480.00
Idelalisib is a kinase inhibitor. In combination with rituximab, it was used for the treatment of relapsed or refractory chronic lymphocytic leukemia...
°ä²¹³Ù²¹±ô´Ç²µ:Ìý
MRRPB5
February 2024
Price: USD 2,900.00
Idelalisib is a kinase inhibitor. In combination with rituximab, it was used for the treatment of relapsed or refractory chronic lymphocytic leukemia...
°ä²¹³Ù²¹±ô´Ç²µ:Ìý
MRRPB5
February 2023
Price: USD 2,900.00
Teniposide(NSC 122819,VM-26)is a chemotherapeutic medication mainly used in the treatment of childhood acute lymphocytic leukemia(ALL). The global...
°ä²¹³Ù²¹±ô´Ç²µ:Ìý
MRRPB5
March 2024
Price: USD 2,900.00
Teniposide(NSC 122819,VM-26)is a chemotherapeutic medication mainly used in the treatment of childhood acute lymphocytic leukemia(ALL). The global...
°ä²¹³Ù²¹±ô´Ç²µ:Ìý
MRRPB5
January 2023
Price: USD 2,900.00
Ìý
